Clinical trials: Intravenous Access
Vascular Access Complication
AccuCath™ Intravenous (IV) Device Used by Vascular Access Team (VAT)
The study will test a hypothesis that the AccuCath™ System will have a higher rate of successful first attempt peripheral intravenous (PIV) placement, higher completion of therapy, fewer complications, longer dwell times, and…
- Trial name
- NCT01937195
- Testing
- AccuCath Intravenous Catheter System
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- C. R. Bard
Veins
Percentage Venous Options in Pediatrics & Adults
VeinViewer® Vision will significantly increase the number of peripheral intravenous catheter access targets perceived by clinicians with experience in intravenous cannulation when compared to the number of access targets that…
- Trial name
- NCT01453335
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Christie Medical Holdings, Inc.
Colorectal Cancer
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess the adverse events and change in disease activity of telisotuzumab adizutecan plus bevacizumab compared…
- Trial name
- AndroMETa-CRC (NCT07525206)
- Testing
- Telisotuzumab adizutecan, Bevacizumab, Trifluridine/Tipiracil
- Where
- 88 sites in United States, Belgium and 8 more
- Volunteers
- 990 people
- Sponsor
- AbbVie
Hunter Syndrome
Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children With Hunter Syndrome
As the HGT-HIT-046 (NCT01506141) and SHP609-302 (NCT02412787) studies are completed and closed, this post-trial access (PTA) program provides TAK-609 to participants in these studies for whom the benefit:risk ratio of continued…
- Trial name
- NCT05795361
- Testing
- Idursulfase-IT
- Where
- 22 sites in United States, Australia and 3 more
- Sponsor
- Takeda
Crohn's Disease, Ulcerative Colitis
Expanded Access to Vedolizumab for Children and Teenagers With Ulcerative Colitis or Crohn's Disease in the USA
The expanded access program (EAP) allows people to gain access to an unlicensed treatment on compassionate grounds. This EAP provides children and teenagers with Ulcerative Colitis (UC) or Crohn's Disease (CD) who completed the…
- Trial name
- NCT06856135
- Testing
- Vedolizumab IV
- Where
- 3 sites in United States
- Sponsor
- Takeda
Pre-Approval Access for Administration of Daratumumab Subcutaneously (SC) in Participants Who Are Unable to Receive Intravenous (IV) Daratumumab
The purpose of this pre-approval access (PAA) program is to provide treatment to participants with serious/life-threatening diseases or conditions.
- Trial name
- NCT04264884
- Testing
- Daratumumab
- Sponsor
- Janssen Research & Development, LLC
Lafora Disease
Intravenous VAL-1221 Lafora Expanded Access Protocol
Only qualified physicians treating a Lafora Disease patient may request VAL-1221 Expanded Access treatment under the Parasail Lafora Expanded Access Protocol (LEAP).
- Trial name
- LEAP (NCT05930223)
- Testing
- VAL-1221
- Sponsor
- Parasail, LLC
BD Prevue II for Peripheral Intravenous Catheter Placement
BD Prevue(TM) II Peripheral Vascular Access System With Cue(TM) Needle Tracking Technology Clinical Study
This post-market study is being conducted to generate safety and performance data on the BD Prevue(TM) II Peripheral Vascular Access System with Cue(TM) Needle Tracking Technology.
- Trial name
- NCT06632496
- Testing
- BD Prevue(TM) II
- Where
- 2 sites in United States
- Volunteers
- 156 people
- Sponsor
- Becton, Dickinson and Company
Airway Control
Rapid Sequence Intubation Drug Delivery Using Intraosseous and IV Access in Pediatric Patients Observational Study
This study will evaluate using intraosseous vascular access and intravenous vascular access to give pediatric patients the necessary medications to perform rapid sequence intubation, for patients with airway difficulties.
- Trial name
- NCT01634867
- Where
- United States
- Sponsor
- Vidacare Corporation
Airway Control
Observational Study of Rapid Sequence Intubation Drug Delivery Using Intraosseous and Intravenous Access.
This study will evaluate using intraosseous vascular access and intravenous vascular access to give patients the necessary medications to perform rapid sequence intubation, for patients with airway difficulties.
- Trial name
- NCT01486407
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Vidacare Corporation
Amyotrophic Lateral Sclerosis
Intermediate-Sized Expanded Access Study
This expanded access protocol is to provide access to the investigational product, SLS-005, to participants with ALS who are not eligible to participate in clinical trials.
- Trial name
- NCT05597436
- Testing
- Trehalose
- Where
- 21 sites in United States
- Sponsor
- Seelos Therapeutics, Inc.
Patients in Need for Intravenous Access
Evaluation of Introcan Safety 3 Closed IV Catheter
Incidence and time of occurrence of blood leakage with the closed intravascular catheter Introcan Safety 3 in comparison to Introcan Safety
- Trial name
- NCT02197013
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- B. Braun Melsungen AG
Uremic Pruritus
Intermediate-Size Patient Population Expanded Access Program for Intravenous Difelikefalin
This is an intermediate-size patient population expanded access protocol for the use of intravenous (IV) difelikefalin for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients…
- Trial name
- NCT05031546
- Testing
- Difelikefalin
- Sponsor
- Cara Therapeutics, Inc.
Bacterial Infections
Expanded Access to Cefiderocol for the Intravenous Treatment of Severe Gram Negative Bacterial Infections
Expanded access may be provided for cefiderocol for qualified patients who have limited treatment options and are not eligible for a clinical trial.
- Trial name
- NCT03780140
- Testing
- Cefiderocol
- Sponsor
- Shionogi
Difficult-to-access Veins for Intravenous Cannulation
Veinplicity for Improved Venous Access: The VIVA Trial
This study will assess the safety and effectiveness of the Veinplicity device to improve the visualization and palpability of difficult-to-access veins for intravenous cannulation.
- Trial name
- NCT03752632
- Testing
- Veinplicity with tourniquet, Tourniquet
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Physeon GmbH
Hypoplasminogenemia
A Treatment Protocol for Expanded Access Administration of Prometic Plasminogen Due to Closure of Clinical Trial
The clinical trial is no longer enrolling and is currently closing and Prometic will continue to provide Plasminogen (Human) under a treatment protocol to subjects in the United States (US) with hypoplasminogenemia requiring…
- Trial name
- NCT03642691
- Testing
- Ryplazim
- Where
- 3 sites in United States
- Sponsor
- Prometic Biotherapeutics, Inc.
Generalized Pustular Psoriasis
An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options
This Expanded Access Program in China is open to people with a serious skin disease called Generalized Pustular Psoriasis (GPP).
- Trial name
- NCT05239039
- Testing
- spesolimab
- Where
- 12 sites in China
- Volunteers
- 39 people
- Sponsor
- Boehringer Ingelheim
Peripheral Venous Catheterization, Difficult Intravenous Access
TruVascular Access - Ultrasound-Guided Vascular Access Study
TruVascular Access - TVA-2026 is a prospective, randomized clinical study evaluating whether ultrasound-guided peripheral vascular access improves first-attempt cannulation success compared with conventional landmark…
- Conditions
- Peripheral Venous Catheterization, Difficult Intravenous Access, Catheterization, Peripheral
- Trial name
- TVA-2026 (NCT07798427)
- Testing
- Ultrasound-Guided Peripheral Vascular Access, Standard Peripheral Vascular Access, Point-of-Care Ultrasound System for Vascular Access Guidance
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Truway Health, Inc.
Gram-Positive Bacterial Infections
Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria
The purpose of this study is to provide daptomycin, an antibiotic, to patients who are failing conventional therapy, or who cannot take approved antibiotics for one reason or another.
- Trial name
- NCT00055198
- Testing
- daptomycin
- Volunteers
- 75 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Healthy
A Study To Access The Safety And Tolerability Of RN316 (PF-04950615) When Administered To Healthy Adult Subjects
The study is designed to determine the safety and tolerability of RN316 when administered intravenously to healthy adult subjects. This is the first time RN316 has been given to humans.
- Trial name
- NCT00991159
- Testing
- RN316
- Where
- 2 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Pfizer